PERTUSSIS — INFECTION NOT UNDER COMPLETE CONTROL
https://doi.org/10.15690/vsp.v13i2.975
Abstract
The article covers the problem of pertussis infection in children of various age groups and causes of high prevalence of this infection in the Russian Federation. According to the author’s opinion the main factors of such a bad situation with this disease are insufficient registration of the cases, increasing amount of parents’ rejections of vaccination with DTP-vaccine, gradual fading of the post-vaccinal immunity and low level of children defense before school, as well as difficulties in diagnostics and atypical clinical course of the disease in adolescents and adults. The issues of modern views on variability of infectious agents, comparative efficacy and immunogenicity of whole cell and acellular vaccines and international experience in usage of acellular DTP-vaccines are reviewed with a special attention. Increasing of the vaccination coverage (due to the switch to the less reactogenic aDTP-vaccines), introduction of booster dosages among younger school children and adolescents, vaccination of pregnant women and cocooning strategy in order to protect newborns and infants under 6 months old can be possible ways to improve epidemiologic situation and control of pertussis infection.
About the Author
V. K. Tatochenko
Scientific Centre of Children Health, Moscow
Russian Federation
Vladimir Tatochenko, Doctor of Medical Science, professor, chief research scientist
Russian Federation
Vladimir Tatochenko, Doctor of Medical Science, professor, chief research scientist
References
1. O sanitarno-epidemiologicheskoy obstanovke v Rossiyskoy Federatsii v 2009 g.: Gosudarstvennyy doklad [On Sanitary and Epidemiologic Situation in the Russian Federation in 2009: State Report]. М.: 2010. 456 p.
2. Hawken S., Manuel D. G., Deeks S. L., Kwong J. C., Crowcroft N. S., Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am. J. Epidemiol. 2012; 176 (11): 1035–1042.
3. Zaytsev Ye. M., Mazurova I. K., Krasnoproshina L. I., Astakhova T. I., Zakharova N. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 1: 56–58.
4. Epidemiologicheskiye aspekty koklyusha v RF. Osobennosti vakt sinoprofilaktiki v sovremennykh usloviyakh [Epidemiological Aspects of Whooping Cough in the Russian Federation. Features of Vaccinal Prevention in Modern Conditions]. М.: MZ RF. 2005. 38 p.
5. Zaytsev Ye. M., Mazurova I. K., Petrova M. S. Zhurnal mikrobiologii, epidemiologii i immunologii — Journal of Epidemiology, Microbiology and Immunology. 2009; 2: 70–75.
6. Narkeviciute I., Kavaliunaite E., Bernatoniene G., Eidukevicius R. Clinical presentation of pertussis in fully immunized children in Lithuania. BMC Infect. Dis. 2005; 5: 40. Doi: 10.1186/ 1471-2334-5-40.
7. Celentano L. P., Massari M., Paramatti D., Salmaso S., Tozzi A. E. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 2005: 24: 761–765.
8. Halperin S. A. The Control of Pertussis — 2007 and Beyond. N. Engl. J. Med. 2007; 356 (2): 6110–6112.
9. Iozefovich O. V., Kharit S. M., Kaplina S. P., Gostev V. V., Sidorenko S. V., Kalinogorskaya O. S., Kvetnaya A. S., Timofeyeva Ye. V., Okuneva M. A. Epidemiologiya i vaktsinoprofilaktika — Epidemiology and Vaccinal Prevention. 2012; 56–59.
10. Schmidtke A. J., Boney K. O., Martin S. W. Population Diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerging Infect. Dis. 2012; 18 (8): 1248–1255.
11. Queenan А. M., Cassiday P. K., Evangelista A. Pertactin-Negative variants of Bordetella pertussis in the United States. N. Engl. J. Med. 2013; 368: 583–584.
12. Rodgers L., Martin S. W., Cohn A., Budd J., Marcon M., Terranella A., Mandal S., Salamon D., Leber A., Tondella M. L., Tatti K., Spicer K., Emanuel A., Koch E., McGlone L., Pawloski L., LemaileWilliams M., Tucker N., Iyer R., Clark T. A., Diorio M. Epidemiologic and laboratory features of a large outbreak of pertussislike illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010–2011. Clin. Infect. Dis. 2013; 56: 322–331.
13. Atwell J. E., Van Otterloo J., Zipprich J., Winter K., Harriman K., Salmon D. A., Halsey N. A., Omer S. B. Nonmedical Vaccine Exemptions and Pertussis in California, 2010. Pediatrics. 2013; doi: 10.1542/peds.2013-0878.
14. Auger К. A., Patrick S. W., Davis M. M. Infant hospitalizations for pertussis before and after Tdap recommendations for adolescents. Pediatrics. 2013; 132: 1149–1155.
15. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., Tozzi A. E., Van Damme P. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect. Dis. 2011; 11 (7): 557–570. Doi: 10.1016/S1473-3099 (11)70007-X.
16. Tartof S. Y., Lewis M., Kenyon C., White K., Osborn A., Liko J., Zell E., Martin S., Messonnier N. E., Clark T. A., Skoff T. H. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013; 131 (4): 1047–1052. Doi: 10.1542/peds.2012-1928.
17. Klein N. P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal. pone.0041928.
18. Liko J., Robison S. G., Cieslak P. R. Priming with whole-cell versus acellular pertussis vaccine. N. Engl. J. Med. 2013; 368: 581–582.
19. Witt M. A., Arias L., Katz P. H., Truong E. T., Witt D. J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine ompared to recipients of acellular pertussis vaccines in a large US cohort. CID. 2013; 56: 1248–1255.
20. Schure R. M., de Rond L., Ozturk K., Hendrikx L., Sanders E., Berbers G., Buisman A. M. Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One. 2012; 7 (7): 41928. Doi: 10.1371/journal.pone.0041928.
21. Thierry-Carstensen B. et al. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults — A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013; http://dx.doi.org/10.1016/j. vaccine.2013.08.034
22. Dias W. O., van der Ark A. A., Sakauchi M. A., Kubrusly F. S., Prestes A. F., Borges M. M., Furuyama N., Horton D. S., Quintilio W., Antoniazi M., Kuipers B., van der Zeijst B. A., Raw I. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother. 2013; 9 (2): Epub ahead of print.
23. Committee opinion no. 566: update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet. Gynecol. 2013; 121 (6): 1411–1414.
24. Hardy-Fairbanks A. J., Pan S. J., Decker M. D., Johnson D. R., Greenberg D. P., Kirkland K. B., Talbot E. A., Bernstein H. H. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr. Infect. Dis. J. 2013; 32 (11): 1257–1260. Doi: 10.1097/INF.0b013e3182a09b6a.
Review
For citations:
Tatochenko V.K. PERTUSSIS — INFECTION NOT UNDER COMPLETE CONTROL. Current Pediatrics. 2014;13(2):78-82. (In Russ.) https://doi.org/10.15690/vsp.v13i2.975
Views:
2243
Email this article 
